Advances in peritoneal dialysis. Conference on Peritoneal Dialysis最新文献_第8页

Relationship between alkaline phosphatase and all-cause mortality in peritoneal dialysis patients. 腹膜透析患者碱性磷酸酶与全因死亡率的关系。

Advances in peritoneal dialysis. Conference on Peritoneal Dialysis Pub Date : 2013-01-01

Paul A Fein, Sara Asadi, Priyanka Singh, William Hartman, Steven Stuto, Jyotiprakas Chattopadhyay, Morrell M Avram

{"title":"Relationship between alkaline phosphatase and all-cause mortality in peritoneal dialysis patients.","authors":"Paul A Fein, Sara Asadi, Priyanka Singh, William Hartman, Steven Stuto, Jyotiprakas Chattopadhyay, Morrell M Avram","doi":"","DOIUrl":"","url":null,"abstract":"Elevated levels of serum alkaline phosphatase (AlkPhos) have been reported to be associated with increased mortality risk in hemodialysis (HD) patients. We examined the association of serum AlkPhos with all-cause mortality in our PD patients. The study enrolled 90 PD patients beginning in 1995. On enrollment, demographics and clinical and biochemical data were recorded. Patients were followed to September 2011. Mean age of the enrollees was 52 years, with 61% being women, and most (81%) being of African descent. Mean and median AlkPhos were 135 U/L and 113 U/L respectively. Mean and maximum follow-up were 2.61 and 16 years respectively. As expected, AlkPhos correlated directly with serum intact parathyroid hormone (r = 0.36, p = 0.003). In a Cox multivariate regression analysis with adjustment for confounding variables, AlkPhos as a continuous (relative risk: 1.016; p = 0.004) anda categorical variable [> 120 U/L and < or = 120 U/L (relative risk: 6.0; p = 0.03)] remained a significant independent predictor of mortality. For each unit increase in enrollment AlkPhos, there was a 1.6% increase in the relative risk of death. Elevated serum AlkPhos is significantly and independently associated with increased mortality risk in our PD patients followed for up to 16 years. AlkPhos should be evaluated prospectively as a potential therapeutic target in clinical practice.","PeriodicalId":7361,"journal":{"name":"Advances in peritoneal dialysis. Conference on Peritoneal Dialysis","volume":"29 ","pages":"61-3"},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31961593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nondialytic therapy for end-stage renal disease is an underutilized care paradigm in the United States: time for a more robust reappraisal of this treatment option. 在美国，终末期肾病的非透析治疗是一种未充分利用的护理模式:是时候对这种治疗方案进行更有力的重新评估了。

Advances in peritoneal dialysis. Conference on Peritoneal Dialysis Pub Date : 2013-01-01

Macaulay A C Onuigbo

{"title":"Nondialytic therapy for end-stage renal disease is an underutilized care paradigm in the United States: time for a more robust reappraisal of this treatment option.","authors":"Macaulay A C Onuigbo","doi":"","DOIUrl":"","url":null,"abstract":"Nondialytic therapy (NDT)--also calledconservative kidney management--is a growing modality of treatment for select chronic kidney disease and end-stage renal disease (ESRD) patients globally. Nevertheless, NDT is rarely practiced in the United States. We set out to investigate NDT activity before initiation of renal replacement therapy in a Northwestern Wisconsin Mayo Clinic ESRD population. Records of all prevalent ESRD patients on chronic hemodialysis in our practice were retrospectively reviewed in May 2012. Dialysis nurses and social workers were informally interviewed to augment the review process. Of the 166 ESRD patients reviewed, 82 (49%) were 70 years of age or older, 46 (28%) were 70-79 years, and 36 (22%) were 80-89 years. Most of these older patients had multiple significant comorbidities (\"multimorbidity\"). Evidence for NDT activity before initiation of renal replacement therapy was virtually nonexistent. The older ESRD patients with multimorbidity experienced frequent hospitalizations. Our preliminary review suggests that their quality of life may have been better with NDT. Almost one half of our ESRD population was made up of people more than 70 years of age, most with multimorbidity. In our practice, NDT is a neglected paradigm, as it is in most U.S. nephrology practices. The place of NDT, actively provided by a specialized multidisciplinary team, for U.S. ESRD patients demands urgent attention and robust reappraisal by U.S. nephrologists.","PeriodicalId":7361,"journal":{"name":"Advances in peritoneal dialysis. Conference on Peritoneal Dialysis","volume":"29 ","pages":"73-6"},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31960475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The experience of dialysis therapy among younger adults. 年轻人透析治疗的经验。

Advances in peritoneal dialysis. Conference on Peritoneal Dialysis Pub Date : 2013-01-01

Hima Bindu Yalamanchili, Peter Murray, Kwabena T Awuah, Paul Harden, Susan H Finkelstein, Fredric O Finkelstein

引用次数: 0

Icodextrin-based continuous ambulatory peritoneal dialysis therapy effectively reduces left ventricular mass index and protects cardiac function in patients with end-stage renal disease. 基于icodextrin的连续动态腹膜透析治疗可有效降低终末期肾病患者左心室质量指数并保护心功能。

Advances in peritoneal dialysis. Conference on Peritoneal Dialysis Pub Date : 2013-01-01

Ikuko Oba, Michiya Shinozaki, Kenji Harada, Takefumi Mori, Hidetoshi Kanai

{"title":"Icodextrin-based continuous ambulatory peritoneal dialysis therapy effectively reduces left ventricular mass index and protects cardiac function in patients with end-stage renal disease.","authors":"Ikuko Oba, Michiya Shinozaki, Kenji Harada, Takefumi Mori, Hidetoshi Kanai","doi":"","DOIUrl":"","url":null,"abstract":"Increased left ventricular mass index (LVMI) is commonly observed in patients undergoing peritoneal dialysis (PD). The present study aimed to determine the effect of icodextrin (Ico) on LVMI in PD patients with maintained residual renal function (RRF). This retrospective study included 18 patients (12 men, 6 women; average age: 62 +/- 10 years) diagnosed with indications for PD therapy and divided into two groups: those treated with Ico (Ico group) and without Ico (non-Ico group). Echocardiography was performed at the beginning of continuous ambulatory PD and after 6 and 12 months. A significant reduction in LVMI (p < 0.01) and an increase in ultrafiltration (p < 0.01) were observed after 6 months of lco treatment and were maintained for 12 months. Ejection fraction was significantly lower in the non-Ico group after 12 months (p < 0.01), but was not altered in the Ico group. Blood pressure, cardiothoracic ratio, urine volume, and N-terminal prohormone of brain natriuretic peptide were unaffected by PD treatment up to 12 months. The year-averaged ultrafiltration and the reduction in LVMI were significantly correlated (p < 0.05). Ico effectively improved LVMI and maintained ejection fraction in end-stage renal disease patients within 1 year from PD initiation. Notably, treatment with Ico resulted in a reduction of LVMI (associated with increased ultrafiltration), with no significant reduction in RRF.","PeriodicalId":7361,"journal":{"name":"Advances in peritoneal dialysis. Conference on Peritoneal Dialysis","volume":"29 ","pages":"14-8"},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31959461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Does bioimpedance analysis or measurement of natriuretic peptides aid volume assessment in peritoneal dialysis patients? 生物阻抗分析或利钠肽测量是否有助于腹膜透析患者的容量评估?

Advances in peritoneal dialysis. Conference on Peritoneal Dialysis Pub Date : 2013-01-01

Andrew Davenport

引用次数: 0

When should icodextrin be started to improve atherosclerosis in peritoneal dialysis patients? 什么时候开始使用醋酸糊精来改善腹膜透析患者的动脉粥样硬化?

Advances in peritoneal dialysis. Conference on Peritoneal Dialysis Pub Date : 2013-01-01

Takeyuki Hiramatsu, Takahiro Hayasaki, Akinori Hobo, Shinji Furuta, Koki Kabu, Yukio Tonozuka, Yoshiyasu Iida

{"title":"When should icodextrin be started to improve atherosclerosis in peritoneal dialysis patients?","authors":"Takeyuki Hiramatsu, Takahiro Hayasaki, Akinori Hobo, Shinji Furuta, Koki Kabu, Yukio Tonozuka, Yoshiyasu Iida","doi":"","DOIUrl":"","url":null,"abstract":"Icodextrin-based peritoneal dialysis (PD) has many advantages over glucose-based PD. The present study aimed to investigate when icodextrin should be started for better management of cardiovascular status (as defined by echocardiography findings) and residual renal function (RRF). We retrospectively analyzed 40 patients treated with continuous ambulatory PD or automated PD. The patients were divided into these groups: Group A: started icodextrin within 2 weeks after PD onset. Group B: started icodextrin 1 year after PD onset. Group C: started icodextrin 2 years after PD onset. Group D: never used icodextrin during the study period. At the start of PD, we observed no significant difference in left ventricular mass index (LVMI) or urine volume (UV) between the groups. At 4 years, LVMI and UV were both significantly improved in group A compared with group D. The amelioration in LVMI was negatively associated with phosphate elimination. Our study showed that icodextrin preserved RRF and ameliorated left ventricular hypertrophy. Moreover, the timing of icodextrin introduction in PD patients influenced the clinical effects, including progression of cardiac hypertrophy and RRF.","PeriodicalId":7361,"journal":{"name":"Advances in peritoneal dialysis. Conference on Peritoneal Dialysis","volume":"29 ","pages":"4-8"},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31959458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Changing the paradigm from contraction of peritoneal dialysis programs to increasing prevalent peritoneal dialysis numbers. 改变范例，从腹膜透析计划的收缩到腹膜透析数量的增加。

Advances in peritoneal dialysis. Conference on Peritoneal Dialysis Pub Date : 2013-01-01

Jennifer Cross, Andrew Davenport

引用次数: 0

The importance of residual renal function in peritoneal dialysis patients. 腹膜透析患者残余肾功能的重要性。

Advances in peritoneal dialysis. Conference on Peritoneal Dialysis Pub Date : 2013-01-01

Jose A Diaz-Buxo, Sarah A White, Rainer Himmele

引用次数: 0

Hemoperitoneum in a peritoneal dialysis patient from a retroperitoneal source. 腹膜透析患者腹膜后出血。

Advances in peritoneal dialysis. Conference on Peritoneal Dialysis Pub Date : 2013-01-01

Cristina Balsera, Steven Guest

引用次数: 0

Icodextrin eliminates phosphate and ameliorates cardiac hypertrophy and valvular calcification in patients with end-stage renal disease and diabetes mellitus undergoing peritoneal dialysis. 在接受腹膜透析的终末期肾病和糖尿病患者中，碘糊精消除磷酸盐并改善心脏肥厚和瓣膜钙化。

Advances in peritoneal dialysis. Conference on Peritoneal Dialysis Pub Date : 2013-01-01

Takeyuki Hiramatsu, Takahiro Hayasaki, Akinori Hobo, Shinji Furuta, Koki Kabu, Yukio Tonozuka, Yoshiyasu Iida

{"title":"Icodextrin eliminates phosphate and ameliorates cardiac hypertrophy and valvular calcification in patients with end-stage renal disease and diabetes mellitus undergoing peritoneal dialysis.","authors":"Takeyuki Hiramatsu, Takahiro Hayasaki, Akinori Hobo, Shinji Furuta, Koki Kabu, Yukio Tonozuka, Yoshiyasu Iida","doi":"","DOIUrl":"","url":null,"abstract":"Among end-stage renal disease (ESRD) patients, cardiovascular disease is a common comorbidity and one of most important factors affecting clinical prognosis. Calcium deposition has been reported to correlate with plasma phosphate. Icodextrin (Ico)-based peritoneal dialysis (PD) has many advantages over glucose (Glu)-based PD. We aimed to identify factors that suppress arteriosclerosis and valvular disease in patients with ESRD and diabetes mellitus (DM) undergoing Ico-based PD. In this retrospective study, we evaluated the effects of Ico-based PD (n = 20) on phosphate elimination and cardiovascular disease progression in patients with ESRD andDM, and we compared the results with those for Glu-based PD (n = 20). Left ventricular mass index (LVMI) and aortic valve calcification (AVC) score were significantly decreased and daily phosphate elimination was significantly increased in the Ico group compared with the Glu group. Furthermore, mean daily phosphate elimination was significantly and negatively correlated with the amelioration in LVMI and AVC score. Our study suggests that, compared with glucose, icodextrin has the ability to eliminate more phosphate from the body, indicating that phosphate elimination might potentially be a means of controlling cardiovascular disease in PD patients with DM.","PeriodicalId":7361,"journal":{"name":"Advances in peritoneal dialysis. Conference on Peritoneal Dialysis","volume":"29 ","pages":"9-13"},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31959459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0